Literature DB >> 12872982

TRAIL, a mighty apoptosis inducer.

Youngleem Kim1, Dai-Wu Seol.   

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a membrane-bound cytokine molecule that belongs to the family of tumor necrosis factor (TNF). TRAIL has been shown to be a potent apoptosis inducer in a wide variety of cancer cells in vitro and to limit tumor growth efficiently in vivo without damaging normal tissues. These features have focused considerable attention on TRAIL as a potential therapeutic agent to treat human cancers. Recent data also suggest the implication of TRAIL in a natural defense mechanism since its abrogation results in certain autoimmune disorders. This review will summarize recent progress in TRAIL research, including understanding of apoptotic signaling, regulation of TRAIL action, and possible therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12872982

Source DB:  PubMed          Journal:  Mol Cells        ISSN: 1016-8478            Impact factor:   5.034


  10 in total

Review 1.  Strategies and mechanisms for host and pathogen survival in acute and persistent viral infections.

Authors:  Maurice R Hilleman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-05       Impact factor: 11.205

2.  From bench to bedside: the growing use of translational research in cancer medicine.

Authors:  Erin M Goldblatt; Wen-Hwa Lee
Journal:  Am J Transl Res       Date:  2010-01-01       Impact factor: 4.060

Review 3.  Protein post-translational modifications in the regulation of cancer hallmarks.

Authors:  Haiying Wang; Liqian Yang; Minghui Liu; Jianyuan Luo
Journal:  Cancer Gene Ther       Date:  2022-04-07       Impact factor: 5.854

4.  Sub-toxic dose of apigenin sensitizes HepG2 cells to TRAIL through ERK-dependent up-regulation of TRAIL receptor DR5.

Authors:  Eun Young Kim; Ji Sun Yu; Mihi Yang; An Keun Kim
Journal:  Mol Cells       Date:  2012-12-04       Impact factor: 5.034

5.  Down-Regulation of Survivin by Nemadipine-A Sensitizes Cancer Cells to TRAIL-Induced Apoptosis.

Authors:  Seong Ho Park; So Jung Park; Joo-Oh Kim; Ji Hyun Shin; Eun Sung Kim; Yoon Kyung Jo; Jae-Sung Kim; So Jung Park; Dong-Hoon Jin; Jung Jin Hwang; Seung Jin Lee; Seong-Yun Jeong; Chaeyoung Lee; Inki Kim; Dong-Hyung Cho
Journal:  Biomol Ther (Seoul)       Date:  2013-01       Impact factor: 4.634

6.  Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL.

Authors:  Gila Kazimirsky; Wei Jiang; Shimon Slavin; Amotz Ziv-Av; Chaya Brodie
Journal:  Stem Cell Res Ther       Date:  2016-10-10       Impact factor: 6.832

7.  Novel Structurally Related Flavones Augment Cell Death Induced by rhsTRAIL.

Authors:  Joanna Bronikowska; Ewelina Szliszka; Edyta Kostrzewa-Susłow; Dagmara Jaworska; Zenon P Czuba; Piotr Bednarski; Wojciech Król
Journal:  Int J Mol Sci       Date:  2017-06-06       Impact factor: 5.923

8.  The lncRNA CASC2 Modulates Hepatocellular Carcinoma Cell Sensitivity and Resistance to TRAIL Through Apoptotic and Non-Apoptotic Signaling.

Authors:  Jichun Sun; Hongbo Xu; Zhao Lei; Zhiqiang Li; Hongwei Zhu; Zhen Deng; Xiao Yu; Xiaoxin Jin; Zhi Yang
Journal:  Front Oncol       Date:  2022-01-25       Impact factor: 6.244

9.  Possible novel therapy for malignant gliomas with secretable trimeric TRAIL.

Authors:  Moonsup Jeong; Yong-Sam Kwon; Soon-Hye Park; Chae-Young Kim; Sin-Soo Jeun; Kang-Won Song; Yong Ko; Paul D Robbins; Timothy R Billiar; Byong-Moon Kim; Dai-Wu Seol
Journal:  PLoS One       Date:  2009-02-20       Impact factor: 3.240

10.  Isoproterenol Enhances Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Human Embryonic Kidney Cells through Death Receptor 5 up-Regulation.

Authors:  Young Woo Eom; Ha Yun Jung; Ji-Eun Oh; Jun-Won Lee; Min-Soo Ahn; Young Jin Youn; Sung Gyun Ahn; Jang Young Kim; Seung-Hwan Lee; Junghan Yoon; Byung-Su Yoo
Journal:  Korean Circ J       Date:  2015-12-29       Impact factor: 3.243

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.